US Bancorp
KPTI icon

US Bancorp’s Karyopharm Therapeutics KPTI Stock Holding History

US Bancorp’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-266
Closed -$22K – 4219
2022
Q3 		$22K Buy
266
+171
+180% +$12.8K ﹤0.01% 2980
2022
Q2 		$7K Sell
95
-120
-56% -$11K ﹤0.01% 3474
2022
Q1 		$24K Buy
215
+31
+17% +$3.86K ﹤0.01% 2977
2021
Q4 		$18K Buy
184
+43
+30% +$4.29K ﹤0.01% 3164
2021
Q3 		$13K Buy
141
+63
+81% +$6.54K ﹤0.01% 3329
2021
Q2 		$12K Buy
78
+66
+550% +$9.58K ﹤0.01% 3343
2021
Q1 		$2K Buy
12
+2
+20% +$421 ﹤0.01% 3708
2020
Q4 		$2K Hold
10
– – ﹤0.01% 3580
2020
Q3 		$2K Hold
10
– – ﹤0.01% 3502
2020
Q2 		$3K Sell
10
-3
-23% -$887 ﹤0.01% 3434
2020
Q1 		$4K Hold
13
– – ﹤0.01% 3316
2019
Q4 		$4K Hold
13
– – ﹤0.01% 3334
2019
Q3 		$2K Sell
13
-269
-95% -$36.5K ﹤0.01% 3417
2019
Q2 		$25K Buy
282
+13
+5% +$1.04K ﹤0.01% 2797
2019
Q1 		$24K Buy
269
+222
+472% +$24.6K ﹤0.01% 2789
2018
Q4 		$7K Buy
+47
New +$7.93K ﹤0.01% 3125
2014
Q3 		– Sell
-47
Closed -$33K – 3539
2014
Q2 		$33K Buy
47
+1
+2% +$465 ﹤0.01% 2662
2014
Q1 		$21K Sell
46
-39
-46% -$19.8K ﹤0.01% 2823
2013
Q4 		$29K Buy
+85
New +$23.5K ﹤0.01% 2624

Other funds holding KPTI

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

US Bancorp's KPTI Position: Q4 2022 in Review

US Bancorp sold out of Karyopharm Therapeutics (KPTI) in Q4 2022, closing a stake of 266 shares — an estimated $22K sold.

US Bancorp first reported a position in KPTI in Q4 2013 and held it in 19 quarters. The position peaked at $33K in Q2 2014. 154 funds tracked by Wall St. Rank hold KPTI as of Q4 2022.

  • US Bancorp reported no remaining Karyopharm Therapeutics position as of Q4 2022 after selling out during the quarter.
  • US Bancorp sold 266 Karyopharm Therapeutics shares in Q4 2022, an estimated $22K.
  • US Bancorp first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 19 quarters.
  • US Bancorp's Karyopharm Therapeutics position peaked at $33K in Q2 2014.
  • 154 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2022.

Based on US Bancorp's 13F filing for Q4 2022, filed 13 Feb 2023.